Active substance
Tretinoin
- SFDA 15
- US FDA 49
- Health Canada 8
- US price lines 12
- NHS prices 1
- Safety 3
SFDA Saudi Arabia — SFDA human drug list
| Trade name | Strength | Form · route | Pack | Public price | Type | Company | Status |
|---|---|---|---|---|---|---|---|
| ACNELIN | 0.05 % | Cream · Topical | 1 Tube | SAR 15.80 | Generic · Prescription | HAYAT PHARMACEUTICAL INDUSTRIES | Valid |
| ACRETIN | 0.05 % | Cream · Topical | 1 Tube | SAR 19.50 | Generic · Prescription | Jamjoom Pharmaceuticals Factory Company | Valid |
| ACRETIN | 0.025 % | Cream · Topical | 1 Tube | SAR 18.85 | Generic · Prescription | Jamjoom Pharmaceuticals Factory Company | Valid |
| AVOTIN- A | 0.05 % | Cream · Topical | 1 Bottle | SAR 17.40 | Generic · Prescription | Middle East Pharmaceutical Industries Co Ltd Avalon Pharma | Valid |
| Tretinoin Dawaa Health | 0.05 % (W/W) | Cream · Topical | 1 Tube | SAR 17.40 | Generic · Prescription | Al Dawaa Medical Services Co Ltd | Valid |
| ACNE TOP 0.05% W-W CREAM | 0.05 % | Cream · Topical | 1 Tube | SAR 14.30 | Generic · Prescription | DEEF PHARMACEUTICAL INDUSTRIES | Withdrawn by MAH · Not Marketed |
| EUDYNA CREAM 0.05% | 0.05 % | Cream · Topical | 1 Tube | SAR 13.65 | NCE · Prescription | Knoll Pharmaceuticals | Invalid · Not Marketed |
| EUDYNA GEL 0.05% | 0.05 % | Gel · Topical | 1 Tube | SAR 13.40 | NCE · Prescription | Knoll Pharmaceuticals | Invalid · Not Marketed |
| OPTIMAL 0.025% GEL | 0.025 % | Gel · Topical | 30 Tube | SAR 7.00 | Generic · Prescription | Pharma International Co. | Withdrawn by MAH · Not Marketed |
| OPTIMAL 0.05% CREAM | 0.05 % | Cream · Topical | 30 Tube | SAR 11.65 | Generic · Prescription | Pharma International Co. | Withdrawn by MAH · Not Marketed |
| RETACNYL 0.025% CREAM | 0.025 % | Cream · Topical | 1 Bottle | SAR 15.35 | Generic · Prescription | GALDERMA | Withdrawn by MAH · Not Marketed |
| RETACNYL 0.05% CREAM | 0.05 % | Cream · Topical | 1 Bottle | SAR 17.80 | Generic · Prescription | GALDERMA | Withdrawn by MAH · Not Marketed |
| RETIN-A CREAM 0.05% | 0.05 % | Cream · Topical | 1 Tube | SAR 21.10 | Generic · Prescription | Janssen-Cilag International NV | Withdrawn by MAH · Not Marketed |
| RETIN-A GEL 0.025% | 0.025 % | Gel · Topical | 1 Tube | SAR 20.75 | Generic · Prescription | Janssen-Cilag International NV | Withdrawn by MAH · Not Marketed |
| SMOODERM CREAM | 0.05 % | Cream · Topical | 1 Tube | SAR 14.40 | Generic · Prescription | DAR ALDAWA | Withdrawn by MAH · Not Marketed |
Indications — CHI Daman Drug Formulary
PHYMATOUS ROSACEA (MILD TO MODERATE); SYSTEMIC LUPUS ERYTHEMATOSUS
US FDA United States — FDA approvals (Drugs@FDA)
| Product | Strength | Form · route | Applicant | Status | First approved |
|---|---|---|---|---|---|
| RETIN-A | 0.1% | cream · topical | BAUSCH | Prescription | 26 Jan 1973 |
| RETIN-A | 0.05% | cream · topical | BAUSCH | Prescription | 19 Jul 1974 |
| RETIN-A | 0.025% | gel · topical | VALEANT INTL | Prescription | 18 Apr 1975 |
| RETIN-A | 0.01% | gel · topical | BAUSCH | Prescription | 17 Oct 1978 |
| RETIN-A | 0.025% | cream · topical | BAUSCH | Prescription | 16 Sep 1988 |
| AVITA | 0.025% | cream · topical | MYLAN PHARMS INC | Prescription | 14 Jan 1997 |
| RETIN-A MICRO | 0.1%; 0.04% | gel · topical | BAUSCH | Prescription | 7 Feb 1997 |
| RETIN-A-MICRO | 0.08%; 0.06% | gel · topical | BAUSCH | Prescription | 7 Feb 1997 |
| TRETINOIN | 0.1% | cream · topical | PADAGIS US | Prescription | 24 Dec 1998 |
| TRETINOIN | 0.025% | cream · topical | PADAGIS US | Prescription | 24 Dec 1998 |
| TRETINOIN | 0.05% | cream · topical | PADAGIS US | Prescription | 24 Dec 1998 |
| TRETINOIN | 0.025% | gel · topical | PADAGIS US | Prescription | 22 Feb 2000 |
| RENOVA | 0.02% | cream · topical | VALEANT PHARMS NORTH | Prescription | 31 Aug 2000 |
| TRETINOIN | 0.01% | gel · topical | PADAGIS US | Prescription | 11 Jun 2002 |
| ATRALIN | 0.05% | gel · topical | DOW PHARM | Prescription | 26 Jul 2007 |
| TRETINOIN | 10MG | capsule · oral | PH HEALTH | Prescription | 24 Oct 2012 |
| TRETINOIN | 0.05% | gel · topical | MYLAN | Prescription | 13 Aug 2015 |
| TRETINOIN | 10MG | capsule · oral | GLENMARK PHARMS LTD | Prescription | 23 Dec 2016 |
| ALTRENO | 0.05% | lotion · topical | DOW PHARM | Prescription | 23 Aug 2018 |
| TRETINOIN | 0.1% | cream · topical | SUN PHARMA CANADA | Prescription | 22 Jan 2019 |
| TRETINOIN | 0.05% | cream · topical | SUN PHARMA CANADA | Prescription | 25 Jan 2019 |
| TRETINOIN | 0.025% | cream · topical | SUN PHARMA CANADA | Prescription | 5 Jan 2023 |
| TRETINOIN MICROSPHERE | 0.08%; 0.06% | gel · topical | ENCUBE | Prescription | 22 Aug 2023 |
| TRETINOIN | 0.1% | cream · topical | ZYDUS LIFESCIENCES | Prescription | 25 Apr 2024 |
| TRETINOIN | 0.1% | cream · topical | ALEMBIC | Prescription | 29 Apr 2024 |
24 more — full table
Canada Canada — marketed products (Health Canada)
| Brand | DIN | Strength | Form · route | Company |
|---|---|---|---|---|
| JAMP TRETINOIN | 02520036 | 10 MG | CAPSULE · ORAL | JAMP PHARMA CORPORATION |
| RETIN-A | 00443794 | 0.05 % / W/W | CREAM · TOPICAL | BAUSCH HEALTH, CANADA INC. |
| RETIN-A | 00443816 | 0.025 % / W/W | GEL · TOPICAL | BAUSCH HEALTH, CANADA INC. |
| RETIN-A MICRO | 02243914 | 0.1 % / W/W | GEL · TOPICAL | BAUSCH HEALTH, CANADA INC. |
| RETIN-A MICRO | 02264633 | 0.04 % / W/W | GEL · TOPICAL | BAUSCH HEALTH, CANADA INC. |
| VESANOID | 02145839 | 10 MG | CAPSULE · ORAL | CHEPLAPHARM ARZNEIMITTEL GMBH |
| VITAMIN A ACID | 01926470 | 0.025 % | GEL · TOPICAL | BAUSCH HEALTH, CANADA INC. |
| VITAMIN A ACID | 01926489 | 0.05 % | GEL · TOPICAL | BAUSCH HEALTH, CANADA INC. |
Prices — United States and England
| Source | Product as listed | Price | Unit / pack | Date |
|---|---|---|---|---|
| US NADAC | TRETINOIN 0.01% GEL | $2.73988 | per GM | 23 Sep 2026 |
| US NADAC | TRETINOIN 0.01% GEL | $2.3019 | per GM | 23 Sep 2026 |
| US NADAC | TRETINOIN 0.025% CREAM | $0.55294 | per GM | 23 Sep 2026 |
| US NADAC | TRETINOIN 0.025% CREAM | $0.45929 | per GM | 23 Sep 2026 |
| US NADAC | TRETINOIN 0.025% GEL | $3.54983 | per GM | 23 Sep 2026 |
| US NADAC | TRETINOIN 0.025% GEL | $2.50019 | per GM | 23 Sep 2026 |
| US NADAC | TRETINOIN 0.05% CREAM | $1.61765 | per GM | 23 Sep 2026 |
| US NADAC | TRETINOIN 0.05% CREAM | $1.05049 | per GM | 23 Sep 2026 |
| US NADAC | TRETINOIN 0.05% GEL | $3.93282 | per GM | 23 Sep 2026 |
| US NADAC | TRETINOIN 0.1% CREAM | $0.91963 | per GM | 23 Sep 2026 |
| US NADAC | TRETINOIN 0.1% CREAM | $0.77008 | per GM | 23 Sep 2026 |
| US NADAC | TRETINOIN 10 MG CAPSULE | $8.53098 | per EA | 23 Sep 2026 |
| NHS Drug Tariff | Tretinoin 10mg capsules | £420.00 | 100 capsule | 1 Oct 2026 |
NADAC: average price US retail pharmacies pay to buy the medicine. NHS Drug Tariff Part VIIIA: basic price reimbursed to pharmacies in England and Wales.
Safety signals and safety-related labeling changes
- US FDA 10 Sep 2025 RETIN-A MICRO — safety-related labeling change
Labeling sections changed: Warnings and Precautions; Adverse Reactions; Use in Specific Populations; Patient Counseling Information / Patient Information / Medication Guide - US FDA 4 Oct 2024 VESANOID — safety-related labeling change
Labeling sections changed: Boxed Warning; Contraindications; Warnings and Precautions; Adverse Reactions; Drug Interactions; Use in Specific Populations; Patient Counseling Information / Patient Information / Medication Guide - US FDA 2 Dec 2019 SOLAGE — safety-related labeling change
Labeling sections changed: Warnings and Precautions; Adverse Reactions; Use in Specific Populations; Patient Counseling Information / Patient Information / Medication Guide
Combinations containing Tretinoin
Values as published by each source: SFDA human drug list (4-2026, as published by the Council of Health Insurance; indications from the CHI Daman Drug Formulary), Drugs@FDA, EMA medicines data, Health Canada Drug Product Database (Open Government Licence – Canada), CMS NADAC, NHS Drug Tariff Part VIIIA (NHSBSA Copyright, Open Government Licence v3.0), WHO Model List of Essential Medicines (CC BY 3.0 IGO; regrouped by active substance, not created by WHO), EMA PRAC, US FDA safety-related labeling changes and MHRA Drug Safety Update (Open Government Licence v3.0). Sources and reuse. Not a substitute for the official registers or the product information.